Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “buy” rating restated by stock analysts at Peel Hunt in a note issued to investors on Thursday.
Several other equities analysts have also recently issued reports on HIK. AlphaValue reiterated a “buy” rating and issued a GBX 2,431 ($30.55) target price on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, November 30th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 2,450 ($30.79) target price on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, December 6th. Jefferies Group LLC boosted their target price on shares of Hikma Pharmaceuticals Plc from GBX 2,000 ($25.14) to GBX 2,065 ($25.95) and gave the company a “buy” rating in a research note on Thursday, December 15th. Numis Securities Ltd cut shares of Hikma Pharmaceuticals Plc to an “add” rating and set a GBX 2,350 ($29.53) target price for the company. in a research note on Friday, March 10th. Finally, HSBC Holdings plc cut shares of Hikma Pharmaceuticals Plc to a “reduce” rating and set a GBX 1,800 ($22.62) target price for the company. in a research note on Friday, March 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. Hikma Pharmaceuticals Plc currently has an average rating of “Buy” and an average price target of GBX 2,353.67 ($29.58).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down 1.39% during trading on Thursday, hitting GBX 1981.00. 708,681 shares of the company’s stock were exchanged. The company has a 50-day moving average of GBX 2,075.05 and a 200-day moving average of GBX 1,920.10. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,575.00 and a 12-month high of GBX 2,703.00. The company’s market cap is GBX 4.75 billion.
The business also recently disclosed a dividend, which will be paid on Thursday, May 25th. Shareholders of record on Thursday, April 6th will be given a dividend of GBX 0.22 ($0.00) per share. The ex-dividend date is Thursday, April 6th. This is a boost from Hikma Pharmaceuticals Plc’s previous dividend of $0.21. This represents a yield of 0.78%.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.